Effect of coenzyme Q10 supplementation on serum of high sensitivity c-reactive protein level in patients with cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

Abstract

Possible effects of coenzyme Q10 (CoQ10) supplement on the serum level of high-sensitivity C-reactive protein (hs-CRP) in cardiovascular diseases (CVDs) remains unclear.Objective:Therefore, this meta-analysis was conducted to investigate its effects on the serum hs-CRP level in patients with CVDs. A comprehensive search was conducted on the EMBASE, MEDLINE, and PubMed Central databases for pertinent papers in English up to November 2016. All randomized controlled trials (RCTs) that studied the effects of supplementation with CoQ10 on the serum of hs-CRP level in cardiovascular patients were included. We used random-effects models (the DerSimonian–Laird method) to estimate the pooled effect of selected studies and the I2 test to assess the between-study heterogeneity. The subgroup analyses were carried out according to the baseline serum hs-CRP, quality assessment score, supplementation dosage, and duration of intervention. Of 205 studies, five trials were eligible for inclusion in this study with 159 participants in the ntervention and 143 participants in the placebo group. Results of the pooled analysis revealed that the CoQ10 supplementation had no significant effect on the serum level of hs-CRP compared with the placebo group (MD: 0.120; 95% = −0.944, 1.185; P = 0.825). Moreover, the subgroup analyses showed the baseline serum hs-CRP, quality assessment score, and duration of intervention can be sources of heterogeneity. The results of this study demonstrated that the beneficial effect of CoQ10 supplementation for patients with CVDs is observed in those who received this supplement for more than 12 weeks and with the baseline serum hs-CRP >3 mg/L.

L-shaped association between dietary coenzyme Q10 intake and high-sensitivity C-reactive protein in Chinese adults: a national cross-sectional study

“…48 A meta-analysis suggested that supplementation with CoQ10 significantly reduced circulating hsCRP in patients whose baseline levels of hsCRP were more than 3 mg L −1 . 51 Combining this meta-analysis with our results, it is suggested that there may be a more significant negative association between dietary CoQ10 and circulating hsCRP in subgroups with higher levels of hsCRP. These speculations need to be further confirmed by cohort studies.…”

“…According to the recent meta-analyses of RCTs, 22,50–53 CoQ10 supplementation may reduce the risk of inflammation-related diseases by partly reducing the levels of several circulating inflammatory markers, including CRP, IL-6, and TNF-α. Zahed et al found that three months of 100 mg per day CoQ10 intervention significantly reduced CRP and thus cardiovascular events in a randomized cross-over clinical trial of 34 patients with end-stage renal disease undergoing dialysis.…”

“…48 A meta-analysis suggested that supplementation with CoQ10 significantly reduced circulating hsCRP in patients whose baseline levels of hsCRP were more than 3 mg L −1 . 51 Combining The data were reported as β (95% CI). Sex, age, the highest level of education, region, total energy intake, physical activity, urbanization index, and alcohol and cigarette consumption were introduced into adjusted models.…”

Clinical Advances in Immunonutrition and Atherosclerosis: A Review

“…However, no changes were observed for CRP or IL-6. Finally, in patients with CVD with baseline serum hs-CRP levels > 3 mg/L, these levels improved after receiving CoQ10 supplementation for more than 12 weeks (146).…”